Procalcitonin Use in Pneumonia Patients in the Critical Care Setting

Not Applicable

Completed

• Conditions: Pneumonia

• Registration Number: NCT01788488
• Lead Sponsor: Mayo Clinic

Brief Summary

The goal of the study is to determine the impact of procalcitonin (PCT)-guided therapy on duration of antibiotic therapy in critical care unit (CCU) patients with suspected pneumonia at Mayo Clinic Health System Eau Claire.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2013-01-25
• Study Start: 2013-02
• Study First Submitted QC: 2013-02-07
• Study First Posted: 2013-02-11
• Primary Completion: 2013-03
• Status Verified: 2013-06
• Study Completion: 2013-06
• Last Update Submitted: 2013-06-21
• Last Update Posted: 2013-06-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 134

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Length of antibiotic therapy	Indefinite	Participants will be followed for the entire time they are on antibiotics to treat pneumonia, an expected average of 30 total antibiotic days.

Secondary Outcome Measures

Name	Time	Method
Length of stay in critical care unit	Indefinite	Participants will be followed for their entire length of stay in the critical care unit, an expected average of 7 days.
Cost	Once	The average cost of antibiotics per patient, measured in US dollars, based on total antibiotic days.
Length of stay in the hospital	Indefinite	Participants will be followed their entire length of stay in the hospital, an expected average of 14 days.

Trial Locations

Locations (1)

Mayo Clinic Health System Eau Claire; 🇺🇸 Eau Claire, Wisconsin, United States